Cetrelimab
- Generic Name
- Cetrelimab
- Drug Type
- Biotech
- CAS Number
- 2050478-92-5
- Unique Ingredient Identifier
- LYK98WP91F
- Background
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Radiation: Conventional radiation therapyRadiation: Hypo-fractioned radiation therapy
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 518
- Registration Number
- NCT04658862
- Locations
- 🇮🇳
Aakash Healthcare Super Speciality Hospital, New Delhi, India
🇦🇷Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina
🇧🇷Fundação Hospitalar São Francisco de Assis, Belo Horizonte, Brazil
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT04640623
- Locations
- 🇺🇸
Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Genesis Healthcare Partners - Genesis Research Greater Los Angeles, Sherman Oaks, California, United States
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8Metastatic Prostate Neuroendocrine CarcinomaAggressive Variant Prostate CarcinomaMetastatic Prostate Small Cell Carcinoma
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04592237
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Castration-Resistant Prostatic Neoplasms
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT03551782
- Locations
- 🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇺🇸Regional Urology LLC, Shreveport, Louisiana, United States
🇺🇸University of California San Francisco (UCSF) - Prostate Cancer Center, San Francisco, California, United States
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-28
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 22
- Registration Number
- NCT03547037
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 125
- Registration Number
- NCT03473743
- Locations
- 🇧🇾
Grodno University Hospital, Grodno, Belarus
🇧🇾State Institution N.N. Alexandrov Republican Scientific and, Lesnoy, Belarus
🇧🇾Minsk city Clinical Oncological Dispensary, Minsk, Belarus
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 136
- Registration Number
- NCT03431350
- Locations
- 🇨🇦
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada
🇺🇸Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
🇺🇸The Urology Center of Colorado, Denver, Colorado, United States
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03357952
- Locations
- 🇧🇪
Algemeen Ziekenhuis Klina, Brasschaat, Belgium
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇧🇪UZBrussel, Brussel, Belgium
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02908906
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.